BRPI0815850A2 - "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico" - Google Patents
"método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico"Info
- Publication number
- BRPI0815850A2 BRPI0815850A2 BRPI0815850-9A2A BRPI0815850A BRPI0815850A2 BR PI0815850 A2 BRPI0815850 A2 BR PI0815850A2 BR PI0815850 A BRPI0815850 A BR PI0815850A BR PI0815850 A2 BRPI0815850 A2 BR PI0815850A2
- Authority
- BR
- Brazil
- Prior art keywords
- response
- schizophrenia
- delaying
- strengthening
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007129568/15A RU2508096C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии |
RU2007129567/15A RU2508106C2 (ru) | 2007-08-01 | 2007-08-01 | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии |
PCT/US2008/009357 WO2009017836A1 (en) | 2007-08-01 | 2008-08-01 | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0815850A2 true BRPI0815850A2 (pt) | 2014-10-07 |
Family
ID=40304696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0815850-9A2A BRPI0815850A2 (pt) | 2007-08-01 | 2008-08-01 | "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico" |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110269777A1 (pt) |
EP (1) | EP2175724A4 (pt) |
JP (1) | JP2010535220A (pt) |
KR (1) | KR20100054812A (pt) |
CN (1) | CN101842010A (pt) |
AU (1) | AU2008282742A1 (pt) |
BR (1) | BRPI0815850A2 (pt) |
CA (1) | CA2719824A1 (pt) |
MX (1) | MX2010001218A (pt) |
WO (1) | WO2009017836A1 (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7837812B2 (en) | 2004-05-21 | 2010-11-23 | Ati Properties, Inc. | Metastable beta-titanium alloys and methods of processing the same by direct aging |
JP2010540439A (ja) | 2007-09-20 | 2010-12-24 | ディー2イー,エルエルシー | 神経保護性の及び認知を向上させる性質を備えた水素化されたピリド[4,3−b]インドール類のフッ素を含有する誘導体、調製するための工程、並びに使用 |
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
BRPI0906244A2 (pt) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit |
CN102046625B (zh) | 2008-03-24 | 2015-04-08 | 梅迪维新技术公司 | 桥连杂环化合物及其使用方法 |
CN102105059B (zh) * | 2008-05-27 | 2015-09-30 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
EP2346332A4 (en) | 2008-10-31 | 2012-08-08 | Medivation Technologies Inc | PYRIDOÝ4,3-BINDOLES CONTAINING RIGID FRAGMENTS |
JP5551708B2 (ja) | 2008-10-31 | 2014-07-16 | メディベイション テクノロジーズ, インコーポレイテッド | アゼピノ[4,5−b]インドール化合物およびその使用方法 |
SG173639A1 (en) | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
WO2010115342A1 (zh) | 2009-04-10 | 2010-10-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 含有四氢吡啶[4,3-b]吲哚衍生物的缓释组合物及该衍生物的制备方法 |
BRPI1006608A2 (pt) | 2009-04-29 | 2015-08-25 | Medivation Technologies Inc | Composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição |
BRPI1006602A2 (pt) * | 2009-04-29 | 2019-01-15 | Medivation Technologies Inc | composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição |
AU2010298169B2 (en) | 2009-09-23 | 2015-10-29 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
CA2775328A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
US9193728B2 (en) | 2010-02-18 | 2015-11-24 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2011103485A1 (en) * | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2011103448A1 (en) * | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
CN104212890A (zh) | 2010-02-24 | 2014-12-17 | 布罗德研究所有限公司 | 诊断传染病病原体及其药物敏感性的方法 |
US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
CA2827642A1 (en) | 2011-02-18 | 2012-11-15 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US9199985B2 (en) | 2011-02-18 | 2015-12-01 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
WO2012112965A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US20150224120A1 (en) * | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
JPWO2014128882A1 (ja) * | 2013-02-21 | 2017-02-02 | 医療法人 和楽会 | 不安うつ病の治療薬 |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
DK2968320T3 (da) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | Organiske forbindelser |
JP6475727B2 (ja) | 2013-12-03 | 2019-02-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規方法 |
BR112016023162B1 (pt) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central |
KR101646962B1 (ko) | 2014-09-29 | 2016-08-10 | 한국과학기술연구원 | CaM 저해활성을 가지는 페노싸이아진 유도체 |
US20160184290A1 (en) * | 2014-12-31 | 2016-06-30 | Paul J. Markovitz | Method of treating schizophrenia |
WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
WO2016205631A1 (en) * | 2015-06-17 | 2016-12-22 | Massachusetts Institute Of Technology | Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders |
RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規塩類および結晶 |
US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
EP3525763A4 (en) | 2016-10-12 | 2020-06-17 | Intra-Cellular Therapies, Inc. | AMORPHE FIXED DISPERSIONS |
EP3558275A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN110337290A (zh) | 2016-12-31 | 2019-10-15 | 比奥克斯塞尔医疗股份有限公司 | 舌下右旋美托咪啶用于治疗激越的用途 |
EP3600325A4 (en) | 2017-03-24 | 2021-01-06 | Intra-Cellular Therapies, Inc. | UNIQUE COMPOSITIONS AND PROCESSES |
US10035795B1 (en) | 2017-04-06 | 2018-07-31 | Korea Institute Of Science And Technology | Phenothiazine derivatives having CaM inhibitory activity |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
KR20200033307A (ko) | 2017-07-26 | 2020-03-27 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
IL272252B2 (en) | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Transformed histories of gamma-carbolines fused with heterocyclics, pharmaceutical preparations containing them and their use for treatment |
WO2019067591A1 (en) | 2017-09-26 | 2019-04-04 | Intra-Cellular Therapies, Inc. | NEW SALTS AND CRYSTALS |
WO2019128991A1 (en) * | 2017-12-26 | 2019-07-04 | Sunshine Lake Pharma Co., Ltd. | Lurasidone solid dispersion and preparation method thereof |
WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
AU2019295699A1 (en) | 2018-06-27 | 2021-01-28 | Arx, Llc | Film formulations containing dexmedetomidine and methods of producing them |
CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
CA3108553A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
JP2022540706A (ja) | 2019-07-19 | 2022-09-16 | バイオエクセル セラピューティクス,インコーポレイテッド | 鎮静作用のないデクスメデトミジン治療レジメン |
WO2021119334A1 (en) | 2019-12-11 | 2021-06-17 | Intra-Cellular Therapies, Inc. | Organic compound |
JP2024507991A (ja) * | 2021-02-26 | 2024-02-21 | バイオエクセル セラピューティクス,インコーポレイテッド | 激越を処置するための方法及び組成物 |
CN115290775A (zh) * | 2022-07-25 | 2022-11-04 | 上海市徐汇区中心医院 | 一种精神类药物质控品、其试剂盒、制备方法及应用 |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS229067B1 (en) * | 1981-08-20 | 1984-04-16 | Svorad Stolc | Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof |
US4672117A (en) * | 1985-09-16 | 1987-06-09 | American Home Products Corporation | Antipsychotic gamma-carbolines |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
US5631265A (en) * | 1994-03-11 | 1997-05-20 | Eli Lilly And Company | 8-substituted tetrahydro-beta-carbolines |
RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
TW470745B (en) * | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
BR0211608A (pt) * | 2001-08-08 | 2006-04-04 | Upjohn Co | 1h-pirido[4,3-b]indóis terapêuticos |
WO2005120463A1 (en) * | 2004-06-09 | 2005-12-22 | Ranbaxy Laboratories Limited | Rapidly disintegrating tablets of risperidone |
WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
AU2008257152A1 (en) * | 2007-05-25 | 2008-12-04 | Medivation Neurology, Inc. | Methods and compositions for stimulating cells |
-
2008
- 2008-08-01 MX MX2010001218A patent/MX2010001218A/es not_active Application Discontinuation
- 2008-08-01 US US12/671,679 patent/US20110269777A1/en not_active Abandoned
- 2008-08-01 KR KR1020107004429A patent/KR20100054812A/ko not_active Application Discontinuation
- 2008-08-01 EP EP08826868A patent/EP2175724A4/en not_active Withdrawn
- 2008-08-01 BR BRPI0815850-9A2A patent/BRPI0815850A2/pt not_active IP Right Cessation
- 2008-08-01 AU AU2008282742A patent/AU2008282742A1/en not_active Abandoned
- 2008-08-01 WO PCT/US2008/009357 patent/WO2009017836A1/en active Application Filing
- 2008-08-01 CN CN200880107277A patent/CN101842010A/zh active Pending
- 2008-08-01 CA CA2719824A patent/CA2719824A1/en not_active Abandoned
- 2008-08-01 JP JP2010519954A patent/JP2010535220A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2175724A1 (en) | 2010-04-21 |
MX2010001218A (es) | 2010-04-07 |
WO2009017836A1 (en) | 2009-02-05 |
AU2008282742A1 (en) | 2009-02-05 |
EP2175724A4 (en) | 2010-09-15 |
CN101842010A (zh) | 2010-09-22 |
KR20100054812A (ko) | 2010-05-25 |
JP2010535220A (ja) | 2010-11-18 |
US20110269777A1 (en) | 2011-11-03 |
CA2719824A1 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815850A2 (pt) | "método para tratar, retardar a progressão, prevenir ou atrasar o desenvolvimento de esquizofrenia em um individuo, composiçã farmaceuticamente aceitável, kit e método para reforçar uma resposta de um individuo a um antipsicótico" | |
BRPI0915986A2 (pt) | composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo | |
HK1216080A1 (zh) | 用於治療或預防草酸鹽相關疾病的組合物和方法 | |
BRPI0716354A2 (pt) | "composiÇço e mÉtodo" | |
ZA200710713B (en) | Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives | |
IL177717A0 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
GB0525041D0 (en) | Methods, assays and compositions for treating retinol-related diseases | |
PT1755391E (pt) | Métodos e composições para o tratamento de neuropatias | |
BRPI0808163A2 (pt) | Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit | |
BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
EP2076116A4 (en) | COMPOSITIONS, METHODS AND DEVICES FOR THE TREATMENT OF LIVER DISEASES | |
BRPI0817478A2 (pt) | composição oralmente biodisponível, métodos para produzir uma composição oralmente biodisponível, e para tratar uma doença em um ser humano, e, kit. | |
BRPI0810956A2 (pt) | "composição, método para controlar de modo preventivo ou curativo e uso da composição" | |
EP2192134A4 (en) | PHOTOSENSITIVE COMPOSITION, PATTERN FORMATION METHOD EMPLOYING THE PHOTOSENSITIVE COMPOSITION, AND COMPOUND USED IN THE PHOTOSENSITIVE COMPOSITION | |
IL185056A0 (en) | Compositions and methods for treating or preventing flaviviridae infections | |
DK2046797T3 (da) | Furo-[3,2-b]pyrrol-3-onderivativer og deres anvendelse som cysteinylproteinaseinhibitorer | |
DE602005013968D1 (de) | Polyorganosiloxan und härtbare zusammensetzung daraus | |
EP2234625B8 (en) | Compositions and methods for treating and preventing skeletal muscle deficiencies | |
BRPI0916102A2 (pt) | "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal" | |
PL378587A1 (pl) | Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli | |
BRPI0809802A2 (pt) | "composição granular para tratamento de água, tablete para tratamento de água, composição para tratamento de água e método de tratamento de água para recreação" | |
ZA200900210B (en) | Compositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism | |
EP2069391A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING EYE DRYING | |
EP2035015A4 (en) | COMPOSITIONS, METHODS AND KITS FOR DRY EYE TREATMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |